Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Entest BioMedical, Inc. in Discussions to Acquire Nanotechnology Delivery System for Cancer Therapy

Abstract:
Entest BioMedical Inc. (OTC PINK: ENTB) announced today that the Company is currently in discussions to acquire a nanotechnology for the delivery of cancer therapeutics in both animals and humans.

Entest BioMedical, Inc. in Discussions to Acquire Nanotechnology Delivery System for Cancer Therapy

San Diego, CA | Posted on June 3rd, 2015

This technology would potentially allow more potent therapeutics to be administered to patients than is currently possible. The reason this is possible is due to the fact that the nanoparticles sequester the drug and allow it to travel throughout the body with minimal toxicity, only releasing the drug directly to the tumor.

A Company spokesman stated: "We are enthusiastic about this potential acquisition. Although Entest has historically focused on veterinary biotechnology, we believe that the acquisition of this nanotechnology would enable us to pursue partnering opportunities in the human market as well as the veterinary market."

####

About Entest BioMedical Inc.
Entest BioMedical Inc. (OTC PINK: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The Company is also pursuing cancer therapeutics for veterinary application.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

For more information, please click here

Contacts:
Entest BioMedical Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404 Phone
619-330-2328 Fax
www.entb.net

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Multistep self-assembly opens door to new reconfigurable materials April 19th, 2019

A hole in one for holographic display: Tiny pinholes in a thin film could pave the way for more widespread applications for 3D holographic displays April 19th, 2019

New fiber-shaped supercapacitor for wearable electronics April 19th, 2019

From nata de coco to computer screens: Cellulose gets a chance to shine: Researchers at Osaka University meticulously measured the optical birefringence of highly aligned cellulose nanofibers, paving the way for sharper television, computer, and smartphone screens April 19th, 2019

Cancer

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models April 11th, 2019

Magnetic nanoparticles can 'burn' cancer cells: Magnetic hyperthermia is still a highly experimental cancer treatment, but new research shows that the therapy is tunable April 7th, 2019

Nanobiotix Receives European Market APPROVAL for Cancer Therapy Hensify (NBTXR3) April 3rd, 2019

Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer April 3rd, 2019

Nanomedicine

A light-activated remote control for cells April 17th, 2019

Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease April 15th, 2019

Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™ April 12th, 2019

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models April 11th, 2019

Announcements

A hole in one for holographic display: Tiny pinholes in a thin film could pave the way for more widespread applications for 3D holographic displays April 19th, 2019

New fiber-shaped supercapacitor for wearable electronics April 19th, 2019

From nata de coco to computer screens: Cellulose gets a chance to shine: Researchers at Osaka University meticulously measured the optical birefringence of highly aligned cellulose nanofibers, paving the way for sharper television, computer, and smartphone screens April 19th, 2019

From 2D to 1D: Atomically quasi '1D' wires using a carbon nanotube template: New bulk synthesis method for nanowires of molybdenum telluride for nanoelectronics April 19th, 2019

Acquisitions/Mergers/Splits

VIS To Acquire GLOBALFOUNDRIES’ Fab 3E In Singapore February 1st, 2019

180 Degree Capital Corp.’s Portfolio Company, TheStreet, Inc., Agrees to Sell Its Institutional Business Units to Euromoney Institutional Investor PLC for $87.3 Million December 6th, 2018

Nanometrics Completes Acquisition of 4D Technology Corporation: The addition of Dynamic Interferometry® expands process control technology solutions November 16th, 2018

Bruker Announces Acquisition of Nanoindenting Leader Hysitron: Acquisition strengthens Bruker’s leading position in nanoanalysis and nanomechanical materials characterization January 24th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project